From : Sopo Belkania <sbelkania@moh.gov.ge>
To : Graeme Robertson <Graeme.Robertson@gilead.com>
Subject : RE: Report April
Cc : Aysan Murtezaoglu <Aysan.Murtezaoglu@gilead.com>; Sean Barr <Sean.Barr@gilead.com>; Maia Lagvilava
Received On : 15.05.2018 11:00
Dear Graeme, Hope you are doing well! Firstly, let me introduce you with Mrs. Maia Lagvilava, Deputy Minister who joined our team few months ago and is now responsible for the Hepatitis C Program. I have cc-ed here in this correspondence and please kindly include or address her in future Hepatitis C Program related communication. Secondly, regarding your request, let me briefly describe the current situation: As you are aware, from the beginning of the program implementation more than 46 000 HCV patients were registered, more than 45 000 out of registered patients have already started treatment and more than 40 000 have completed treatment. Patients flow within the HCV Elimination Program is being gradually changed. Recently, gradual decrease of patients’ inflow in the treatment component have been observed. According to our preliminary analysis, the decrease of the patients’ inflow is caused by several reasons, including financial and geographical barriers. At this stage, the Ministry of Labour, Health and Social Affairs of Georgia is working on the activities to scale up HCV Elimination Program throughout the country from June or July 2018, by establishing minimum one HCV service provider in each municipality and cities of local governance. Primary healthcare facilities will be involved in HCV Elimination Program to deliver comprehensive services within diagnostic and treatment components, including 10 PHC facilities in Tbilisi, 2 in Kutaisi, 2 in Batumi and 1 in Zugdidi. In total, 84 centers will be involved in HCV program implementation which will ensure geographical access as much as possible. Implementation of the decentralization project significantly depends on introduction of the Sofosbuvir/Velpatasvir, as more simplified and cost-effective regime of HCV treatment (no additional medication is required). In particular, at this stage, the total cost of diagnostic tests for treatment uptake (including genotype, ultrasound research, elastography, etc.) equals 369 GEL / 147.6 $, out of which patient’s co-payment is 258.3 GEL / 103.3 $, in case of treatment with Pangenotipic medicines, diagnostic algorithm will be significantly simplified and the total cost of diagnostic tests will be about 230 GEL / 92 $ and co-payment about 160 GEL / 65 $. We believe that this intervention will significantly increase the patients’ involvement in the program (About 1500-2500 patients per month). In addition, we are actively discussing the issue to launch the program on the territory of Autonomous Republic of Abkhazia, that will enable us to use Harvoni remained on the balance of the Ministry for the treatment of patients living on the territory of Abkhazia. We would highly appreciate if you could consider the possibility of delivering Sofosbuvir/Velpatasvir. In case of your consent, with great pleasure, we will make a new order and determined the necessary quantity of the drug. Best regards, Sopo Belkania Head of HR Management and International Relations Department Ministry of Labor, Health and Social Affairs of Georgia 144 A.Tsereteli Avenue, 0159, Tbilisi, Georgia Mobile number: +995 599 22 32 32 -----Original Message----- From: Graeme Robertson [mailto:Graeme.Robertson@gilead.com] Sent: Friday, May 4, 2018 1:11 PM To: Sopo Belkania Cc: Aysan Murtezaoglu; Sean Barr Subject: Re: Report April Dear Sopo Please could you kindly provide an updated supply / Shipping forecast so we can ensure timely supply of Harvoni. Specifically what date will you need the next shipment of Harvoni Thank you for the update Best wishes Graeme Sent from my iPhone > On 2 May 2018, at 08:53, Sopo Belkania wrote: > > Dear Graeme and Aysan, > > Hope this email find you well. > > Please find attached report for April month. > > Best regards, > > Sopo Belkania > Head of HR Management and International Relations Department Ministry > of Labor, Health and Social Affairs of Georgia > 144 A.Tsereteli Avenue, 0159, Tbilisi, Georgia Mobile number: +995 599 > 22 32 32 > > > > > DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England